论文部分内容阅读
目的观察分析依达拉奉治疗心源性脑栓塞的临床可行性。方法将72例心源性脑栓塞患者,随机分为观察组和对照组,每组36例。2组患者均应用抗血小板、抗凝等药物常规治疗,在此基础上,对照组给予血栓通治疗,观察组给予依达拉奉治疗,观察2组患者治疗前后神经功能恢复情况、谷胱甘肽过氧化物酶(GSH-Px)及活性氧簇(ROS)数值变化,不良反应发生情况。结果治疗后,2组患者GSH-Px水平均高于治疗前,ROS水平均低于治疗前,且观察组GSH-Px、ROS水平改善情况优于对照组(P均<0.05);治疗后,2组NIHSS评分较治疗前均降低,且观察组NIHSS评分低于对照组(P<0.05);观察组不良反应发生率为27.8%,低于对照组的55.6%(P<0.05)。结论依达拉奉能有效缓解心源性脑栓塞患者体内的氧化应激水平,改善患者的神经受损功能,且不良反应发生情况较少,具有可行性。
Objective To observe the clinical feasibility of edaravone in the treatment of cardioembolism. Methods 72 patients with cardiogenic cerebral embolism were randomly divided into observation group and control group, 36 cases in each group. Both groups were given routine anti-platelet and anticoagulant drugs. On the basis of this, the control group was treated with Xueshuantong and the observation group was treated with edaravone. The recovery of neurological function, glutathione Peptides peroxidase (GSH-Px) and reactive oxygen species (ROS) changes in the number of adverse reactions. Results After treatment, GSH-Px levels in both groups were significantly higher than those before treatment, ROS levels were lower than before treatment, and GSH-Px and ROS levels in observation group were better than those in control group (all P <0.05) The NIHSS scores in both groups were lower than those before treatment, and the NIHSS scores in the observation group were lower than those in the control group (P <0.05). The incidence of adverse reactions in the observation group was 27.8%, which was lower than that in the control group (55.6%, P <0.05). Conclusion Edaravone can effectively relieve the oxidative stress in patients with cardiogenic cerebral embolism and improve the neurological impairment in patients with less adverse reactions, which is feasible.